In spite of the fact that safe and effective vaccines have been available for over 40 years,hepatitis B virus(HBV)remains a major public health problem,as there are 296 million chronically HBV-infected individuals wor...In spite of the fact that safe and effective vaccines have been available for over 40 years,hepatitis B virus(HBV)remains a major public health problem,as there are 296 million chronically HBV-infected individuals worldwide and 820000 HBV-related deaths taking place every year.Achieving the goal of HBV cure remains a challenge due to the particularities of the HBV cycle underlying viral persistence.The new understanding of HBV biology and antiviral immune responses has allowed to identify novel drug targets.This has led to a renewed interest in developing new curative strategies and combinations for HBV.In the present review,we aim to summarise the biological and clinical challenges associated with chronic HBV infection.Moreover,we consider the lessons that have been learnt in the past years regarding the preclinical and clinical evaluation of compounds against HBV and how this is driving the field to explore new directions.展开更多
基金supported by the French National Research Agency Investissements d’Avenir Programme(CirB-RNA project–ANR-17-RHUS-0003)by the European Union’s Horizon 2020 research and innovation programme under grant agreement number 847939(IP-cure-B Project)to FZby the Agence Nationale pour la Recherche sur le SIDA et les hepatites virales(ANRS)to AARS(ECTZ206376)and FZ.
文摘In spite of the fact that safe and effective vaccines have been available for over 40 years,hepatitis B virus(HBV)remains a major public health problem,as there are 296 million chronically HBV-infected individuals worldwide and 820000 HBV-related deaths taking place every year.Achieving the goal of HBV cure remains a challenge due to the particularities of the HBV cycle underlying viral persistence.The new understanding of HBV biology and antiviral immune responses has allowed to identify novel drug targets.This has led to a renewed interest in developing new curative strategies and combinations for HBV.In the present review,we aim to summarise the biological and clinical challenges associated with chronic HBV infection.Moreover,we consider the lessons that have been learnt in the past years regarding the preclinical and clinical evaluation of compounds against HBV and how this is driving the field to explore new directions.
